Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Analyst Ratings

Analyst Ratings

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings

Where Kimco Realty Stands With Analysts

By Benzinga Insights
July 15, 12:13 PM
Within the last quarter, Kimco Realty (NYSE:KIM) has observed the following analyst ratings:

KIM

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Equal-Weight on Rhythm Pharmaceuticals, Raises Price Target to $8

By Benzinga Newsdesk
July 15, 12:13 PM
Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Equal-Weight and raises the price target from $4 to $8.

RYTM

Read More
1 minute read
  • Analyst Ratings

JMP Securities Maintains Market Outperform Rating for Remitly Global: Here’s What You Need To Know

By Benzinga Insights
July 15, 12:08 PM
JMP Securities has decided to maintain its Market Outperform rating of Remitly Global (NASDAQ:RELY) and lower its price target from $22.00 to $14.00. Shares of Remitly Global are trading up 1.3% over the last 24 hours, at $8.56 per share.

RELY

Read More
1 minute read
  • Analyst Ratings

UBS Maintains Buy Rating for JPMorgan Chase: Here’s What You Need To Know

By Benzinga Insights
July 15, 12:08 PM
UBS has decided to maintain its Buy rating of JPMorgan Chase (NYSE:JPM) and lower its price target from $134.00 to $126.00. Shares of JPMorgan Chase are trading up 3.49% over the last 24 hours, at $111.77 per share. A move to $126.00 would account for a 12.73% increase from the current share price.

JPM

Read More
1 minute read
  • Analyst Ratings

Stifel Maintains Buy Rating for MercadoLibre: Here’s What You Need To Know

By Benzinga Insights
July 15, 12:08 PM
Stifel has decided to maintain its Buy rating of MercadoLibre (NASDAQ:MELI) and lower its price target from $1200.00 to $1000.00. Shares of MercadoLibre are trading up 3.77% over the last 24 hours, at $680.38 per share. A move to $1000.00 would account for a 46.98% increase from the current share price.

MELI

Read More
1 minute read
  • Analyst Ratings

Morgan Stanley Maintains Overweight Rating for Inari Medical: Here’s What You Need To Know

By Benzinga Insights
July 15, 12:08 PM
Morgan Stanley has decided to maintain its Overweight rating of Inari Medical (NASDAQ:NARI) and lower its price target from $108.00 to $93.00. Shares of Inari Medical are trading up 0.74% over the last 24 hours, at $73.70 per share.

NARI

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Equal-Weight on Regency Centers, Lowers Price Target to $57.5

By Benzinga Newsdesk
July 15, 12:06 PM
Morgan Stanley analyst Richard Hill maintains Regency Centers (NASDAQ:REG) with a Equal-Weight and lowers the price target from $63 to $57.5.

REG

Read More
4 minute read
  • Analyst Ratings
  • Earnings
  • News

Nasdaq (NDAQ) To Report Q2 Earnings: What’s In The Cards?

By Zacks
July 15, 12:04 PM
Nasdaq, Inc. (NASDAQ: NDAQ) is slated to report second-quarter 2022 earnings on Jul 20, before the opening bell. The company delivered an earnings surprise in each of the last four quarters, the average being 5.9%.

ABCB

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Equal-Weight on Pulmonx, Lowers Price Target to $19

By Benzinga Newsdesk
July 15, 12:03 PM
Morgan Stanley analyst David Lewis maintains Pulmonx (NASDAQ:LUNG) with a Equal-Weight and lowers the price target from $30 to $19.

LUNG

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Equal-Weight on Physicians Realty Trust, Lowers Price Target to $16

By Benzinga Newsdesk
July 15, 12:00 PM
Morgan Stanley analyst Richard Hill maintains Physicians Realty Trust (NYSE:DOC) with a Equal-Weight and lowers the price target from $17.5 to $16.

DOC

Posts pagination

Previous 1 … 4,272 4,273 4,274 … 4,420 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service